On November 29, 2017, Treatment Action Group (TAG) hosted a webinar on suboptimal immune recovery despite HIV suppression by antiretroviral therapy.

Presented by Richard Jefferys, TAG’s Basic Science, Vaccines and Cure Project Director, the webinar reviewed the possible causes and consequences of suboptimal immune recovery, as well as discussed the current lack of potential interventions to promote immune reconstitution in people with persistently low CD4 T cell counts despite HIV suppression.

Nelson Vergel from PoWeR described his own experiences with limited immune recovery, and discussed an advocacy meeting he initiated with the US Food & Drug Administration (FDA) regarding the use of their orphan drug designation as a means to encourage the development of new therapies for this population.

Video of the webinar is below, and a PDF version of the slides with HTML links to references can be downloaded above.